JORGE LUJAN-ZILBERMANN, M.D.

Plain English
This study looked at how to effectively compare the effectiveness of topical corticosteroids (a type of skin treatment) by using different statistical methods. Researchers analyzed data from 11 skin studies and found that a simpler model called the Emax model was most effective in describing the data, with a new method providing better estimates and less variability in results. These findings suggest that the guidelines used by the FDA for testing these medications should be updated to include clearer instructions on which statistical methods to use for better accuracy. Who this helps: This helps doctors and researchers by providing clearer guidelines for evaluating skin treatments.

Plain English
The study looked at how well a booster dose of the meningococcal vaccine works in children and young people with HIV who had already received an initial dose. Researchers found that 98% of participants showed a positive immune response after the booster, with 88% to 94% responding effectively depending on the specific type of bacteria (serogroup) targeted by the vaccine. This is important because it shows that the booster can provide strong protection against serious bacterial infections, even for those who didn't start with high antibody levels. Who this helps: This helps HIV-infected children and youth by enhancing their protection against meningococcal disease.

Plain English
This study examined the effects of a medication called valganciclovir on newborns with symptomatic congenital cytomegalovirus (CMV) disease. Researchers compared giving the drug for 6 months versus just 6 weeks and found that while short-term hearing outcomes were similar, longer-term hearing improved more in those treated for 6 months (73% improved or stayed normal at 12 months compared to 57% in the 6-week group) and had better developmental scores (like language skills). These findings highlight the potential for longer treatment to lead to better hearing and development outcomes over time. Who this helps: This benefits newborns with symptomatic congenital CMV disease and their families.

Plain English
The study looked at how vitamin D3 supplements affected a substance called Fibroblast Growth Factor 23 (FGF23) in young people with HIV who were treated with a specific medication, tenofovir disoproxil fumarate (TDF). After 12 weeks of taking the supplements, FGF23 levels increased by an average of 7.7 pg/ml in those taking TDF and vitamin D3, while other groups either saw no change or a decrease in FGF23 levels. This is significant because it shows that vitamin D supplementation has different effects depending on whether the individual is using TDF, which could impact how doctors manage vitamin D and potentially the health of their patients. Who this helps: This helps HIV-positive youths and their doctors in managing treatment plans.

Plain English
This study looked at how certain genetic differences affect the antibody response to the meningococcal vaccine in young people living with HIV. Researchers found that those with specific variations in the TLR2 and TLR4 genes had better initial antibody responses, achieving a significant increase in antibody levels. Specifically, at four weeks, individuals with the TLR2-2408-G/A genotype were 3.3 times more likely to have this increased response compared to those with the TLR2-G/G genotype, and those with the TLR4-12874-A/A genotype showed similar results. Who this helps: This helps HIV-infected youth by identifying genetic factors that influence their vaccine response.

Plain English
This study looked at how testing for drug resistance in HIV helps manage treatment for children and teenagers with the virus. Researchers followed 57 young patients who underwent this testing and found that over half (50.9%) had their medication changed afterward. Importantly, those whose treatment was adjusted showed a significant improvement, with 31.5% becoming undetectable for the virus compared to only 7% of those who did not change their treatment. Who this helps: This benefits children and adolescents living with HIV.

Plain English
This study examined the effects of the HIV medication tenofovir disoproxil fumarate (TDF) on kidney function, vitamin D levels, and bone health in young people living with HIV. Researchers found that those taking TDF had lower kidney function and phosphate reabsorption, and higher levels of parathyroid hormone, which indicates a shift in vitamin D metabolism. Specifically, those with the highest levels of tenofovir showed increased vitamin D binding protein but lower free vitamin D, suggesting a hidden vitamin D deficiency linked to TDF use. Who this helps: This research benefits patients taking TDF for HIV treatment by highlighting potential side effects related to bone and mineral health.

Plain English
This research looked at how genetic factors might affect vitamin D levels in young people living with HIV. The study found that certain genetic variations, particularly one known as rs222020, made it much less likely for these youth to have sufficient vitamin D, with a odds ratio of 0.31 indicating a strong association. Understanding these genetic links is important because it helps identify which young patients might be at greater risk for vitamin D deficiency, allowing for targeted interventions. Who this helps: This helps patients living with HIV and their healthcare providers.

Plain English
This study looked at how vitamin D3 affects certain health markers in young people aged 18-25 who are infected with HIV and taking a specific medication called tenofovir. The research found that after 12 weeks, 95% of those who took vitamin D3 had enough vitamin D in their blood, up from 48% at the start, and their levels of parathyroid hormone decreased, which is a positive outcome linked to better bone health. This matters because it shows that vitamin D3 can improve important health markers in HIV-infected youth on tenofovir. Who this helps: Patients with HIV, particularly those on tenofovir treatment.

Plain English
This study investigated the effects of monthly vitamin D3 supplements (50,000 IU) on vitamin D levels in young people aged 18-24 living with HIV, especially those on a specific medication called efavirenz. After 12 weeks of treatment, 93% of those who were vitamin D deficient at the start had sufficient vitamin D levels, and their average vitamin D concentration increased significantly from 21.9 to 35.9 ng/ml. This matters because many youth with HIV are low on vitamin D, and safe supplementation can effectively elevate their levels without any harmful side effects. Who this helps: This helps patients with HIV and their doctors by offering a safe way to address vitamin D deficiency.

Plain English
Researchers tested whether a meningococcal vaccine was safe and effective in HIV-infected children ages 2-10, giving some children two doses and tracking their immune response over time. The vaccine was safe with only mild side effects, and most children developed protective immunity after vaccination—though protection against two of the four disease types (serogroups A and C) faded significantly within a year. These results show that HIV-infected children can safely receive this vaccine and benefit from it, but they may need booster shots more frequently than other children to maintain protection against all disease types.

Plain English
Researchers tested whether giving HIV-infected youth one or two doses of a meningitis vaccine produced better immune protection. They found that two doses—given six months apart—worked significantly better than one dose, with two to five times more youth developing protective antibodies against the disease. The vaccine worked well in youth with stronger immune systems, but performed poorly in those with very weak immune systems, even when given twice. **Why it matters:** This research shows doctors should give two doses of this meningitis vaccine to HIV-infected patients with adequate immune function to maximize protection, but also highlights that severely immunocompromised patients need additional strategies since the vaccine alone doesn't protect them adequately.

Plain English
This study looked at how well children with HIV can understand and make decisions about their health compared to children without HIV. Researchers found that while children with HIV scored lower in thinking skills and daily living abilities, their ability to make healthcare decisions was similar to that of their peers without HIV. This matters because it shows that children with HIV can still be involved in their medical care, which is crucial for managing their health effectively. Who this helps: This helps children with HIV and their healthcare providers.

Plain English
This study looked at the safety and effectiveness of a meningococcal vaccine in young people aged 11 to 24 who are infected with HIV. Out of 319 participants, only 3.1% had mild and temporary side effects, while 52% showed a good immune response to at least one type of meningococcal bacteria after getting the vaccine. This matters because it shows that while the vaccine is safe for HIV-infected youth, they may not respond as well as healthy peers, especially those with more serious health conditions. Who this helps: This helps HIV-infected adolescents and their healthcare providers.

Plain English
This study looked at what happens when children and teens, who were born with HIV, stop their HIV medication without a plan. Out of 405 patients, 72 (about 18%) stopped their treatment, with an average age of 12.8 years and a mean interruption of 14 months. The findings showed that most of these young people experienced a drop in their immune function (CD4+ T-cells), and two had serious health problems related to AIDS during the follow-up period of about 19 months. Who this helps: This information is important for healthcare providers managing HIV treatment in children and teens.

Plain English
This study looked at two children with HIV who developed Cushing syndrome and adrenal insufficiency due to taking ritonavir (a medication for HIV) alongside inhaled steroids. The two cases show that using these inhaled steroids in kids on HIV treatment needs careful evaluation because it can lead to serious health issues. This matters because it highlights the importance of monitoring and adjusting treatments to avoid harmful side effects in vulnerable patients. Who this helps: This helps doctors treating children with HIV.

Plain English
This study looked at children with a serious infection called pneumococcal meningitis to see how the timing of the antibiotic vancomycin affected their outcomes. Among 114 children studied, 10 (9%) died, and more than half of the survivors had hearing loss. It was found that giving vancomycin too soon (in less than 2 hours after the first antibiotic) was linked to a higher chance of hearing loss, so doctors might want to wait at least 2 hours before starting vancomycin. Who this helps: This helps doctors treat children with pneumococcal meningitis more effectively.

Plain English
This research paper looks at how to diagnose HIV infection in infants and children, highlighting the challenges in detecting the virus in very young patients. It finds that new tests can quickly diagnose HIV in newborns and lead to early treatment, significantly improving the chances of preserving their immune health. The study also emphasizes that traditional methods work well for older children and adolescents. Who this helps: This benefits infants and children who are at risk of HIV, ensuring they receive timely treatment.

Plain English
This study looked at how to better diagnose and monitor HIV infections in infants and children. It highlighted new lab techniques that can quickly and accurately determine if a child has HIV and help track how well treatments are working. This is important because it can lead to better care and outcomes for young patients with HIV. Who this helps: Patients, especially infants and children with HIV.

Plain English
This study looked at a condition called immune restoration disease (IRD) in children with HIV who were starting treatment with powerful antiretroviral therapy (HAART). Researchers found that after starting HAART, 7 out of 61 children experienced herpes zoster (shingles), particularly those with low immune cell counts at the start and those who had previously had chickenpox without enough protective antibodies. This is important because it highlights a specific health risk (shingles) that can arise in children recovering from HIV, which can help doctors better manage the care of these patients. Who this helps: This helps doctors and HIV-infected children, especially those recently starting treatment.

Plain English
This study looked at using a virus called Sendai, which is related to the human parainfluenza virus, as a potential vaccine to protect against croup, a common respiratory illness in children. The researchers found that the Sendai vaccine was well-tolerated by healthy adults and led to a positive immune response in 3 out of 9 participants, even though some had prior exposure to the human virus. These findings highlight the promise of Sendai as a vaccine option to help prevent serious infections in young children, who are most at risk. Who this helps: This helps infants and children who are at risk for severe respiratory infections.

Plain English
This study looked at a test that detects HIV in newborns who may have been exposed to the virus through their mothers. Researchers examined records of 190 infants and found that the test accurately identified whether an infant had HIV 100% of the time during the first nine months of life. This means the test is very reliable for ensuring that exposed infants are not infected, which is crucial for their health and care. Who this helps: This helps infants born to HIV-infected mothers and their healthcare providers.

Plain English
This study looked at respiratory virus infections in children who received stem cell transplants at St. Jude Children's Research Hospital between 1994 and 1997. Out of 281 transplant cases, 11% (32 patients) developed a respiratory virus infection within the first year, mostly caused by a specific virus called human parainfluenza virus type 3. Understanding these infections is important because they can complicate recovery and treatment for young patients after a stem cell transplant. Who this helps: This helps patients who undergo stem cell transplants and their doctors by highlighting risks related to infections.

Plain English
This study looked at 86 children with pneumococcal meningitis to understand how antibiotic resistance affects their health outcomes. It found that children whose infections were resistant to penicillin had a lower risk of hearing loss and higher white blood cell counts, while those with resistance to cefotaxime experienced longer fevers. These findings matter because they help doctors predict how different antibiotic resistances may impact treatment and recovery in children with this serious infection. Who this helps: This helps patients and doctors treating children with pneumococcal meningitis.